Sharifi Laleh, Pourpak Zahra, Fazlollahi Mohammad Reza, Bokaie Saied, Moezzi Hamid Reza, Kazemnejad Anoushirvan, Moin Mostafa
Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Dept. of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Iran J Public Health. 2015 Sep;44(9):1212-8.
High prevalence and increasing rate of asthmatic patients around the word witnesses the high burden of asthma. We have limited data on asthma burden and economic costs in Iran. This study aimed to find direct and indirect economic costs of asthma and their association with some background factors in one of the referral tertiary centers for adult patients with asthma.
We surveyed asthma related economic costs of 197 adult patients who referred to Milad Hospital, Tehran, Iran from Jun 2007 to January 2010. The patients were followed up for a period of one-year ±1 month and asthma related costs and its control status were registered.
Patients were consisted of 125 (64.1%) females and 70 (35.9%) males. Total cost of asthma was 590.22 ±32.18 USD for one patient per one year, the cost of drug, paraclinic, doctor visit, hospitalization, emergency, transportation, and absent days were 327.02, 4.76, 35.44, 3.82, 0.26, 113.03, 105.89 USD respectively. Men showed a significant elevation in their total (P=0.009) and drug costs (P=0.028). In addition, we found significant differences between total asthma costs and asthma control status (P=0.002).
According to the high proportion of asthma, related cost compare to Total Income of an Iranian family, the necessity of public coverage of health assurance is quite clear. We suggest that improving asthma management and accessibility to specialized treatment centers can result in decreasing asthma medication and transportation costs as major direct and indirect asthma related costs.
全球哮喘患者的高患病率和不断上升的发病率表明哮喘负担沉重。我们对伊朗哮喘负担和经济成本的数据有限。本研究旨在确定一家成人哮喘转诊三级中心中哮喘的直接和间接经济成本及其与一些背景因素的关联。
我们调查了2007年6月至2010年1月转诊至伊朗德黑兰米拉德医院的197例成年患者的哮喘相关经济成本。对患者进行了为期一年±1个月的随访，并记录了哮喘相关成本及其控制状况。
患者包括125名（64.1%）女性和70名（35.9%）男性。每位患者每年的哮喘总成本为590.22±32.18美元，药物、门诊、就诊、住院、急诊、交通和缺勤天数的成本分别为327.02、4.76、35.44、3.82、0.26、113.03、105.89美元。男性的总成本（P=0.009）和药物成本（P=0.028）显著升高。此外，我们发现哮喘总成本与哮喘控制状况之间存在显著差异（P=0.002）。
鉴于哮喘的高比例以及与伊朗家庭总收入相比的相关成本，公共健康保险覆盖的必要性非常明显。我们建议，改善哮喘管理和增加获得专科治疗中心的机会可降低哮喘药物和交通成本，这是哮喘相关的主要直接和间接成本。
